Eli Lilly and Co
Novo Nordisk vs. Eli Lilly: Analysts weigh in as the obesity-drug battle heats up
COPENHAGEN, Denmark — Analysts are paying close attention to Novo Nordisk and Eli Lilly , as the battle to dominate the weight loss drug market heats up. Europe’s largest company Novo Nordisk has dominated headlines since anti-obesity medication took off. It produces weight-loss and diabetes drugs Wegovy and Ozempic and saw its shares rise exponentially […]
Read More
Biden administration to release prices for first 10 drugs subject to landmark Medicare negotiations
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services building in Washington, D.C., on Oct. 6, 2022. Anna Moneymaker | Getty Images The Biden administration on Thursday will release prices for the first 10 prescription drugs that were subject to landmark negotiations between drugmakers and […]
Read More
Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug market
An Eli Lilly & Co. Zepbound injection pen, March 28, 2024. Bloomberg | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Novo Nordisk and Eli Lilly have so far dominated the booming market for a class of weight loss and diabetes drugs. […]
Read More
Digital health company Ro launches GLP-1 insurance-coverage checker to help patients navigate costs
Zoom In IconArrows pointing outwards The direct-to-consumer health-care startup Ro launched a new free tool Tuesday to help patients determine whether their insurance covers a buzzy class of weight loss and diabetes drugs called GLP-1s. Most insurance plans cover GLP-1s when they are used to treat diabetes, so those patients can usually avoid the roughly […]
Read More
Stocks making the biggest premarket moves: KeyCorp, Starbucks, JetBlue, Eli Lilly and more
Check out the companies making the biggest moves in premarket trading: KeyCorp — Shares of the Cleveland-based regional bank jumped 18% after the announcement of a minority investment from The Bank of Nova Scotia. The deal gives Scotiabank 14.9% of KeyCorp’s common stock for roughly $2.8 billion in cash. Starbucks — Shares of the coffee […]
Read More
Stocks making the biggest moves midday: Eli Lilly, Under Armour, Warner Bros. Discovery and more
Eli Lilly — The drug maker’s stock surged 8% after the firm reported second-quarter earnings and revenue that blew past expectations. Eli Lilly also hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike. Under Armour — Shares popped 19% after the athletic […]
Read More
Stocks making the biggest moves premarket: Eli Lilly, Under Armour, Warner Bros. Discovery and more
Check out the companies making headlines in premarket trading. Eli Lilly — The drug maker’s stock surged 8% in premarket trading after the firm reported second-quarter earnings and revenue that blew past expectations. Eli Lilly also hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss […]
Read More
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020. Mike Blake | Reuters Eli Lilly on Thursday reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and […]
Read More
Stock futures fall after Wednesday’s afternoon market slide: Live updates
Stock market futures were little changed on Thursday morning as Wall Street sought to stabilize following several dramatic swings in recent days. Futures tied to the Dow Jones Industrial Average fell 17 points, or about 0.05%. S&P 500 futures slipped 0.12%, while Nasdaq 100 futures gained 0.1%. The move in futures comes after stocks were […]
Read More
Eli Lilly reports earnings Thursday. Here’s what Wall Street is watching
Investors want to know whether Eli Lilly is seeing the same pricing pressures on its blockbuster weight loss drug Zepbound that Novo Nordisk experienced with its competing drug Wegovy in the second quarter. Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street’s expectations. Shares are reeling, down 8%, after […]
Read More